Press Release
00/CMX/80
21st August 2000
 

IBM implements ChemScan RDI for microbial monitoring in hard disc manufacturing facility

 

At a recent open seminar in Nuremburg, Dr Gerhard Pieper from IBM in Mainz (Germany) presented details of their implementation of the ChemScan RDI rapid microbiology test system (Chemunex SA, France) for the real-time monitoring and control of microbial contamination in their state-of-the-art hard disk manufacturing facility.

The manufacture of hard disks and semiconductors requires the highest level of cleanliness possible before the disks go through a coating process. This is done by washing machines which use ultra-pure water. The presence of microbial contamination, unlike inert particles, is particularly problematic as organisms can multiply to relatively high levels. Other monitoring methods used in this industry like LPC (liquid particle count) or TOC (total organic carbon) are not always sensitive enough to detect this contamination before they multiply to a critical level.

Dr Pieper had identified a number of critical control areas within the washing machines and the manufacturing facility that could be prone to microbial contamination. IBM had previously used traditional plate counting methods to monitor microbial contamination in these areas. However, Dr Pieper explained that these tests are not ideal since they require 3-5 days to provide results, may not detect all micro-organisms, are labour intensive and expensive when out-sourced to contract laboratories (many facilities do not have microbiology laboratories).

In evaluating the situation, IBM concluded that they wanted to have real-time microbiology results that allowed proactive monitoring and control of these critical manufacturing operations. However, as many facilities do not have microbiologists, any new testing method had to be easy to use without investment in new laboratories, provide results that required no interpretation (direct counts), be comparable at their facilities world-wide and at a reasonable cost.

Initially methods based on epifluorescence microscopy and ATP bioluminescence were evaluated and rejected due to the need for highly trained operators, repeatability of measurements, high analysis time and a lack of detection sensitivity.

IBM then completed an extensive 2 month evaluation of the ChemScan RDI which is based on membrane filtration of samples, fluorescent labelling of single live microbial cells trapped on the surface of the membrane and their detection and counting using laser scanning analysis in the ChemScan RDI instrument. They concluded that the new method had the sensitivity to detect and count down to one micro-organism in samples within 1 hour of sample collection, did not require any investment in special laboratory facilities and could be used by production personnel after 1 days training.

Dr Pieper explained that the Mainz facility currently use the system for improving control and for the routine monitoring of both the ultra-pure water systems and the cleaning machines. He indicated that the availability of sensitive results in near real-time allows them to control microbial contamination at the lowest level and to optimise cleaning procedures. This guaranties the best achieveable machine performance and improved monitoring costs overall.

Commenting after the presentation, Dr Michael Brailsford, Director of Marketing & Sales at Chemunex said, "After establishing the ChemScan RDI as a new innovative method for rapid testing of high purity water systems in our first target market within the pharmaceutical industry, we have been working hard to expand its application into other industries. The semiconductor market was an obvious target, where the need for monitoring low level microbial contamination is at least as important." Dr Brailsford continued, "To enter this market with two of the initial installations at IBM, the second unit is installed in the USA, is obviously very exciting for us and has provided a solid platform for the continued introduction of ChemScan RDI to this market".

 
- ends -
 

Issued on behalf of Chemunex by HCC•De Facto Consultants.
For more information please contact:

Dr Sarah Pattinson HCC•De Facto (UK) +44 (0) 20 7496 3300
Dr Mike Brailsford Chemunex (France) +33 (0) 149 59 20 00

Return to Index

Contact Us News & Events Literature Library Products Company Profile Home